Featured Research

from universities, journals, and other organizations

New insight into selective binding properties of infectious HIV

Date:
December 21, 2009
Source:
Henry M. Jackson Foundation for the Advancement of Military Medicine
Summary:
Free infectious HIV-1 is widely thought to be the major form of the virus in the blood of infected persons. However researchers have demonstrated that essentially all of the infectious virus particles can bind to the surface of red blood cells isolated from each of 30 normal (non-infected) human donors.

Free infectious HIV-1 is widely thought to be the major form of the virus in the blood of infected persons. U.S. Military HIV Research Program (MHRP) researchers, however, have demonstrated that essentially all of the infectious virus particles can bind to the surface of red blood cells isolated from each of 30 normal (non-infected) human donors.

The results were published on December 15 in PLoS One. The lead investigators, Dr. Zoltan Beck and Dr. Carl Alving, researchers with MHRP in the Division of Retrovirology, Walter Reed Army Institute of Research (WRAIR), explain that the data show that although infectious HIV-1 virus particles that bind to red blood cells comprise only a small amount, perhaps as little as a mean of 2.3% of a typical HIV-1 preparation, erythrocyte-bound HIV-1 is then approximately 100-fold more infectious than free (non-cell-bound) HIV-1 for infection of target cells.

The study concludes that infectious virions constitute only a small fraction of a typical HIV-1 preparation and that, in a laboratory setting, all of the infectious virions can bind to red blood cells and other non-permissive cells (i.e., cells that cannot be infected). If this is true in HIV-infected humans it could mean that red blood cell-bound HIV-1 might be more important than free virus for transmission of infectious HIV-1 to target cells that can be infected.

Dr. Alving says, "If the same behavior of binding of infectious HIV-1 to red blood cells occurs in humans, it might be possible that red blood cell-bound infectious virions are protected from degradation or immune attack."

Dr. Beck adds, "This study suggests that erythrocytes might serve as an important, and perhaps hidden, reservoir for infectious HIV-1 virions."


Story Source:

The above story is based on materials provided by Henry M. Jackson Foundation for the Advancement of Military Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Beck et al. Human Erythrocytes Selectively Bind and Enrich Infectious HIV-1 Virions. PLoS ONE, 2009; 4 (12): e8297 DOI: 10.1371/journal.pone.0008297

Cite This Page:

Henry M. Jackson Foundation for the Advancement of Military Medicine. "New insight into selective binding properties of infectious HIV." ScienceDaily. ScienceDaily, 21 December 2009. <www.sciencedaily.com/releases/2009/12/091215102101.htm>.
Henry M. Jackson Foundation for the Advancement of Military Medicine. (2009, December 21). New insight into selective binding properties of infectious HIV. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/12/091215102101.htm
Henry M. Jackson Foundation for the Advancement of Military Medicine. "New insight into selective binding properties of infectious HIV." ScienceDaily. www.sciencedaily.com/releases/2009/12/091215102101.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins